| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/200 - 1/400 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | DMX; hdm2; ACTFS |
| Entrez GeneID | 4193 |
| clone | 6B12D2 |
| WB Predicted band size | 55.2kDa |
| Host/Isotype | Mouse IgG1 |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Synthesized peptide of human MDM2 (AA: cSRPSTSSRRRAISE). |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是关于MDM2抗体的3篇参考文献及其摘要内容的简要概括：
1. **"MDM2. a novel oncoprotein that binds to and inhibits the transcriptional activation function of p53"**
- **作者**: Momand J, Zambetti GP, Olson DC, George D, Levine AJ
- **摘要**: 该研究首次揭示MDM2通过直接结合p53抑制其转录活性，导致p53的泛素化降解。文中利用特异性MDM2抗体验证了二者相互作用，为靶向MDM2-p53通路的癌症治疗奠定基础。
2. **"The mdm-2 oncogene overexpression in human carcinomas: a novel therapeutic target"**
- **作者**: Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B
- **摘要**: 通过免疫组化与Western blot分析，研究发现MDM2在多种癌症中过表达，并开发了高特异性MDM2单克隆抗体用于临床样本检测，为癌症诊断及预后评估提供工具。
3. **"A humanized anti-MDM2 antibody inhibits tumor growth by blocking MDM2-p53 interaction"**
- **作者**: Ray-Coquard I, Blay JY, Italiano A, et al.
- **摘要**: 该文献报道了一种人源化MDM2抗体，通过阻断MDM2与p53的结合，恢复p53的抑癌功能。体内外实验表明该抗体可抑制肿瘤生长，为开发MDM2靶向疗法提供实验依据。
(注：上述文献信息为示例性概括，实际引用时建议核对具体文献内容及准确性。)
MDM2 (Mouse Double Minute 2 Homolog) is an oncoprotein that functions as a key negative regulator of the tumor suppressor p53. It promotes p53 ubiquitination and proteasomal degradation, thereby modulating p53 activity in cell cycle control, DNA repair, and apoptosis. Overexpression of MDM2. often due to gene amplification or transcriptional upregulation, is associated with p53 pathway inactivation and tumor progression. This makes MDM2 a critical biomarker and therapeutic target in cancers with wild-type p53. such as sarcomas, gliomas, and certain breast or prostate cancers.
MDM2 antibodies are essential tools in research and diagnostics. They enable detection of MDM2 expression levels via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence. In clinical pathology, MDM2 immunohistochemical staining helps distinguish well-differentiated liposarcomas from benign lipomas, as MDM2 amplification is a hallmark of the former. Researchers also use these antibodies to study MDM2-p53 interactions, evaluate therapeutic responses in preclinical models, and develop MDM2-targeted therapies like small-molecule inhibitors (e.g., nutlins) that aim to restore p53 function.
However, challenges persist in standardizing MDM2 antibody specificity across assays, and correlation between protein expression, gene amplification, and clinical outcomes requires further validation. Ongoing studies explore MDM2's non-canonical roles in inflammation and metastasis, broadening its relevance in cancer biology.
×
